miR-106b-5p: Clinical assay data show that miR-106b-5p is characterized by significantly high expression in the peripheral blood of epilepsy patients, and its pathological mechanism of action involves transcriptional repression of rejection guidance molecule A (RGMa), which in turn activates the RGMa-Rac1-JNK/p38 MAPK signaling cascade network (Li et al., 2017; Wang et al., 2015; Yu et al., 2021). This evidence concerns the gene RGMA and epilepsy.